Plasma-derived Portfolio
Immunodeficiencies, Autoimmune diseases, Hypovolemia, Surgical Bleeding
CommercialActive
Key Facts
Indication
Immunodeficiencies, Autoimmune diseases, Hypovolemia, Surgical Bleeding
Phase
Commercial
Status
Active
Company
About Prothya Biosolutions
Prothya Biosolutions is a global provider of plasma-derived medicinal products and services, formed in 2021 through the integration of Plasma Industries Belgium and Sanquin Plasma Products. The company combines over 60 years of legacy expertise in plasma fractionation with a mission to deliver life-saving therapies for patients with immunological and critical care needs. It operates a dual business model, commercializing its own branded products while offering CDMO services to other healthcare organizations. Prothya is positioned as a specialized player in the stable and growing plasma therapeutics market.
View full company profile